Furthermore, tumor infiltrating T cells in the mouse cohort that received hexatherapy have higher proliferative capacity (Ki67+) and have significantly less exhausted phenotype showing less PD-1 and CTLA-4- expression. The gene discussed is RPL17; the disease is neoplasm.